R
Riyaz Shah
Researcher at Maidstone and Tunbridge Wells NHS Trust
Publications - 32
Citations - 5935
Riyaz Shah is an academic researcher from Maidstone and Tunbridge Wells NHS Trust. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 17 publications receiving 5094 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: The LUX-Lung 3 study as mentioned in this paper investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epIDERmal growth factors receptor 2 (HER2/ERbB2), and ErbbB4 and has wide-spectrum preclinical activity against EGFR mutations.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Journal ArticleDOI
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S.S. Ramalingam,Ying Cheng,C. Zhou,Yuichiro Ohe,Fumio Imamura,Byoung Chul Cho,Meng-Chih Lin,Margarita Majem,Riyaz Shah,Yuri Rukazenkov,A. Todd,Aleksandra Markovets,J.C. Barrett,Juliann Chmielecki,Jhanelle E. Gray +14 more
Journal ArticleDOI
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell,Urania Dafni,Enriqueta Felip,Alessandra Curioni-Fontecedro,Oliver Gautschi,Solange Peters,Bartomeu Massuti,Ramon Palmero,Santiago Ponce Aix,Enric Carcereny,Martin Früh,Miklos Pless,Sanjay Popat,Athanasios Kotsakis,Sinead Cuffe,Paolo Bidoli,Adolfo Favaretto,Patrizia Froesch,Noemi Reguart,Javier Puente,Linda Coate,Fabrice Barlesi,Daniel Rauch,Michael Thomas,Carlos Camps,José Gómez-Codina,Margarita Majem,Rut Porta,Riyaz Shah,Emer Hanrahan,Roswitha Kammler,Barbara Ruepp,Manuela Rabaglio,M. Kassapian,Niki Karachaliou,Rachel Tam,David S. Shames,Miguel Angel Molina-Vila,Rolf A. Stahel +38 more
TL;DR: The BELIEF trial provides further evidence of benefit for the combined use of erlotinib and bevacizumab in patients with NSCLC harbouring activating EGFR mutations.
Journal ArticleDOI
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
James Chih-Hsin Yang,Martin Schuler,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Robert M. Lorence,Mehdi Shahidi,Lecia V. Sequist +19 more
TL;DR: This global study investigated the efficacy and safety of A compared with pemetrexed/cisplatin in pts with EGFR mutation positive advanced lung adenocarcinoma and found treatment with A led to a significantly prolonged PFS vs PC.